Evidence map›Paper›PMID 42162242›Full record

ArticleNpj imaging2026

Noninvasive in vivo imaging of NF-κB activation predicts immunotherapy response in solid tumors.

Dimitri Stowbur, Roman Mehling, Philipp Knopf, Barbara Francisca Schörg, Dominik Sonanini, Danielle Arnold-Schild, Irene Gonzalez-Menendez, Leticia Quintanilla-Martinez, Birgit Fehrenbacher, Martin Schaller and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Npj imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Dimitri Stowbur *Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tübingen, Tübingen, Germany.
Roman Mehling *Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tübingen, Tübingen, Germany.
Philipp KnopfWerner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tübingen, Tübingen, Germany.
Barbara Francisca SchörgWerner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tübingen, Tübingen, Germany.
Dominik SonaniniWerner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tübingen, Tübingen, Germany.
Danielle Arnold-SchildInstitute of Immunology, University Medical Center Mainz, Mainz, Germany.
Irene Gonzalez-MenendezCore Facility Histology, Faculty of Medicine Tübingen, University Hospital Tübingen, Tübingen, Germany.
Leticia Quintanilla-MartinezCluster of Excellence iFIT (EXC 2180) "Image Guided and Functionally Instructed Tumor Therapies", Tübingen, Germany.
Birgit FehrenbacherDepartment of Dermatology, Eberhard Karls University, Tübingen, Germany.
Martin SchallerDepartment of Dermatology, Eberhard Karls University, Tübingen, Germany.
Harald CarlsenDepartment of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, Ås, Norway.
Snehlata KumariFrazer Institute, Faculty of Health, Medicine and Behavioural Science, The University of Queensland, Brisbane, QLD, Australia.
Bernd Jürgen PichlerWerner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tübingen, Tübingen, Germany.
Manfred KneillingWerner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tübingen, Tübingen, Germany. manfred.kneilling@med.uni-tuebingen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer immunotherapy improves survival, yet many patients exhibit primary or acquired resistance. We established a combinatorial immunotherapy (COMBO) consisting of tumor antigen-specific Th1 cells and dual immune checkpoint blockade and aimed to noninvasively identify sites of immune activation associated with therapeutic response. Using

Identifiers

PMID42162242
PMCPMC13230985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.